Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Enliven Therapeutics, Inc. (ELVN)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$44.79-5.21%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for ELVN yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain disciplined capital allocation including recent debt issuance | A supporting condition in Enliven Therapeutics, Inc.'s published investment case. The stated target is complete planned equity offering of ~8.9 million shares in 2026-Q2. | Intact | failure to complete planned capital raise | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative clinical-development company, not an established earnings compounder: it is loss-making, and recent financial performance is weak. The long-term thesis is in a watch state, with management’s progress on ELVN-001 mixed and overall evidence confidence low.
The evidence does not provide a valuation comparison or a clear account of market expectations, so whether ELVN is cheap or expensive versus peers is unclear. No fragility gates fired, which suggests no specific fragility signal in this snapshot, but it does not establish that expectations are modest.
Near term, losses and clinical-development spending are likely to continue; quarterly operating expenses rose as research and development advanced. Cash was $895 million at the end of 2026-Q2 after a June offering, while the planned Phase 3 ENABLE-2 start in the second half of 2026 or before year-end remains a key execution test. The August earnings miss and elevated industry miss risk add uncertainty, despite a stronger Healthcare sector backdrop.
Over the next few quarters, the thesis hinges on whether management initiates ENABLE-2 on schedule and provides the planned regulatory and clinical updates while controlling cash use. Sector support could strengthen if VRTX, REGN, and MRNA continue to report strong results and guidance; misses or weaker guidance could weaken that tailwind. A further weakening in jobs data could also increase recession concerns for cyclical names.
For the 1-3 year view, ELVN remains a high-risk clinical-development story with meaningful cash resources but weak recent performance and key execution milestones ahead. The evidence is limited and low-confidence, so the thesis depends heavily on trial progress, spending discipline, and sector conditions. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Advance clinical development of therapeutic candidates |
| A primary condition in Enliven Therapeutics, Inc.'s published investment case. The stated target is achieve key clinical milestones in ongoing trials. |
| Improving |
| failure to meet expected clinical milestones or trial setbacks |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Control operating expenses to manage cash burn | A primary condition in Enliven Therapeutics, Inc.'s published investment case. The stated target is operating loss better than -$27.8M in next 4 quarters. | Intact | operating loss worsens beyond -$27.8M | Operating income: $-36.045M FY2026-Q3; GAAP. Published target: operating loss better than -$27.8M in next 4 quarters. Target period is not explicitly aligned with this observation. Nov 5, 2026-36,045,000 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-2.31 → $-2.27 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-2.31 | $7,143 | 4 / 7 |
| 2026-07-25 | $-2.31 | $7,143 | 4 / 7 |
| 2026-07-26 | $-2.31 | $7,143 | 4 / 7 |
| 2026-07-27 | $-2.31 | $7,143 | 4 / 7 |
| 2026-07-28 | $-2.31 | $7,143 | 4 / 7 |
| 2026-07-29 | $-2.31 | $7,143 | 4 / 7 |
| 2026-07-30 | $-2.31 | $7,143 | 4 / 7 |
| 2026-07-31 | $-2.31 | $7,143 | 4 / 7 |
| 2026-08-01 | $-2.31 | $7,143 | 4 / 7 |
| 2026-08-02 | $-2.33 | $7,140 | 4 / 7 |
| 2026-08-03 | $-2.33 | $7,140 | 4 / 7 |
| 2026-08-04 | $-2.33 | $7,140 | 4 / 7 |
| 2026-08-05 | $-2.33 | $7,140 | 4 / 7 |
| 2026-08-06 | $-2.31 | $7,143 | 4 / 7 |
| 2026-08-07 | $-2.22 | $6,250 | 4 / 6 |
| 2026-08-08 | $-2.29 | $16,670 | 4 / 3 |
| 2026-08-09 | $-2.29 | $16,670 | 4 / 3 |
| 2026-08-10 | $-2.29 | $16,670 | 4 / 3 |
| 2026-08-11 | $-2.22 | $6,250 | 4 / 6 |
| 2026-08-12 | $-2.22 | $6,250 | 4 / 6 |
| 2026-08-13 | $-2.29 | $7,140 | 4 / 7 |
| 2026-08-14 | $-2.22 | $6,250 | 4 / 6 |
| 2026-08-15 | $-2.22 | $6,250 | 4 / 7 |
| 2026-08-16 | $-2.22 | $6,250 | 4 / 7 |
| 2026-08-17 | $-2.22 | $6,250 | 4 / 7 |
| 2026-08-18 | $-2.22 | $6,250 | 4 / 7 |
| 2026-08-19 | $-2.22 | $6,250 | 4 / 7 |
| 2026-08-20 | $-2.26 | $5,556 | 4 / 7 |
| 2026-08-21 | $-2.26 | $5,556 | 5 / 8 |
| 2026-08-22 | $-2.26 | $5,556 | 5 / 8 |
| 2026-08-23 | $-2.26 | $5,556 | 5 / 8 |
| 2026-08-24 | $-2.26 | $5,556 | 5 / 8 |
| 2026-08-25 | $-2.26 | $5,556 | 5 / 8 |
| 2026-08-26 | $-2.26 | $5,556 | 5 / 8 |
| 2026-08-27 | $-2.26 | $5,556 | 5 / 8 |
| 2026-08-28 | $-2.26 | $5,556 | 5 / 8 |
| 2026-08-29 | $-2.26 | $5,556 | 5 / 8 |
| 2026-08-30 | $-2.26 | $5,556 | 5 / 8 |
| 2026-08-31 | $-2.26 | $5,556 | 5 / 8 |
| 2026-09-01 | $-2.26 | $5,556 | 5 / 8 |
| 2026-09-02 | $-2.26 | $5,556 | 5 / 8 |
| 2026-09-03 | $-2.26 | $5,556 | 5 / 8 |
| 2026-09-04 | $-2.26 | $5,556 | 5 / 8 |
| 2026-09-05 | $-2.26 | $5,556 | 5 / 8 |
| 2026-09-06 | $-2.26 | $5,556 | 5 / 8 |
| 2026-09-07 | $-2.26 | $5,556 | 5 / 8 |
| 2026-09-08 | $-2.26 | $5,556 | 5 / 8 |
| 2026-09-09 | $-2.26 | $5,556 | 5 / 8 |
| 2026-09-10 | $-2.26 | $6,250 | 5 / 8 |
| 2026-09-11 | $-2.26 | $6,250 | 5 / 8 |
| 2026-09-12 | $-2.26 | $6,250 | 5 / 8 |
| 2026-09-13 | $-2.26 | $6,250 | 5 / 8 |
| 2026-09-14 | $-2.26 | $6,250 | 5 / 8 |
| 2026-09-15 | $-2.26 | $6,250 | 5 / 8 |
| 2026-09-16 | $-2.26 | $6,250 | 5 / 8 |
| 2026-09-17 | $-2.26 | $6,250 | 5 / 8 |
| 2026-09-18 | $-2.26 | $6,250 | 5 / 8 |
| 2026-09-19 | $-2.26 | $6,250 | 5 / 8 |
| 2026-09-20 | $-2.26 | $6,250 | 5 / 8 |
| 2026-09-21 | $-2.26 | $6,250 | 5 / 8 |
| 2026-09-22 | $-2.26 | $6,250 | 5 / 8 |
| 2026-09-23 | $-2.26 | $6,250 | 5 / 8 |
| 2026-09-24 | $-2.26 | $6,250 | 5 / 8 |
| 2026-09-25 | $-2.26 | $6,250 | 5 / 8 |
| 2026-09-26 | $-2.26 | $6,250 | 5 / 8 |
| 2026-09-27 | $-2.26 | $6,250 | 5 / 8 |
| 2026-09-28 | $-2.26 | $6,250 | 5 / 8 |
| 2026-09-29 | $-2.26 | $6,250 | 5 / 8 |
| 2026-09-30 | $-2.26 | $6,250 | 5 / 8 |
| 2026-10-01 | $-2.26 | $6,250 | 5 / 8 |
| 2026-10-02 | $-2.28 | $5,556 | 6 / 9 |
| 2026-10-03 | $-2.29 | $5,000 | 6 / 9 |
| 2026-10-04 | $-2.29 | $5,000 | 7 / 9 |
| 2026-10-05 | $-2.29 | $5,000 | 7 / 9 |
| 2026-10-06 | $-2.29 | $5,000 | 7 / 9 |
| 2026-10-07 | $-2.29 | $5,000 | 7 / 9 |
| 2026-10-08 | $-2.29 | $5,000 | 7 / 9 |
| 2026-10-09 | $-2.29 | $5,000 | 7 / 9 |
| 2026-10-10 | $-2.29 | $5,000 | 7 / 9 |
| 2026-10-11 | $-2.29 | $5,000 | 7 / 9 |
| 2026-10-12 | $-2.29 | $5,000 | 7 / 9 |
| 2026-10-13 | $-2.29 | $5,000 | 7 / 9 |
| 2026-10-14 | $-2.29 | $5,000 | 7 / 9 |
| 2026-10-15 | $-2.29 | $5,000 | 7 / 9 |
| 2026-10-16 | $-2.29 | $5,000 | 7 / 9 |
| 2026-10-17 | $-2.29 | $5,000 | 7 / 9 |
| 2026-10-18 | $-2.29 | $5,000 | 7 / 9 |
| 2026-10-19 | $-2.29 | $5,000 | 7 / 9 |
| 2026-10-20 | $-2.29 | $5,000 | 7 / 9 |
| 2026-10-21 | $-2.27 | $5,000 | 7 / 10 |
| 2026-10-22 | $-2.27 | $5,000 | 7 / 10 |
| 2026-10-23 | $-2.27 | $5,000 | 8 / 10 |
| 2026-10-24 | $-2.27 | $5,000 | 8 / 10 |
| 2026-10-25 | $-2.27 | $5,000 | 8 / 10 |
| 2026-10-26 | $-2.27 | $5,000 | 8 / 10 |
| 2026-10-27 | $-2.27 | $5,000 | 8 / 10 |
| 2026-10-28 | $-2.27 | $5,000 | 8 / 10 |
| 2026-10-29 | $-2.27 | $5,000 | 8 / 10 |
| 2026-10-30 | $-2.27 | $5,000 | 8 / 10 |
| 2026-10-31 | $-2.27 | $5,000 | 8 / 10 |
| 2026-11-01 | $-2.27 | $5,000 | 8 / 10 |
| 2026-11-02 | $-2.27 | $5,000 | 8 / 10 |
| 2026-11-03 | $-2.27 | $5,000 | 8 / 10 |
| 2026-11-04 | $-2.27 | $5,000 | 8 / 10 |
| 2026-11-05 | $-2.27 | $5,000 | 8 / 10 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 14 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 1 recorded
1 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.